CVRx Q4 Loss Widens to $0.46, Revenue Climbs 4.5% to $16.02M
CVRx posted a fourth-quarter loss of $0.46 per share versus a $0.42 consensus, worsening from a $0.43 loss a year ago, while revenue rose 4.5% to $16.02M, narrowly topping forecasts. The stock has slid 14.4% year-to-date, with Q1 consensus EPS at -$0.51 on $14.5M revenue.
1. Q4 Financial Results
CVRx reported a net loss of $0.46 per share for the quarter ended December 31, 2025, compared to a $0.43 per-share loss in the prior year period. Revenue for the quarter reached $16.02 million, up 4.5% year-over-year.
2. Comparison to Estimates
The $0.46 loss missed the Zacks Consensus Estimate of a $0.42 loss by 9.5%, while revenue narrowly beat the $16.00 million consensus by 0.15%. Adjusted figures exclude non-recurring items.
3. Outlook and Analyst Estimates
Current consensus for Q1 calls for a $0.51 loss per share on $14.5 million in revenue, and full-year estimates stand at a loss of $1.84 per share on $65.24 million in sales. Analysts will monitor revisions following management commentary.
4. Stock Performance and Industry Context
CVRx shares have declined 14.4% year-to-date, underperforming the S&P 500’s 1.4% gain. The company operates in the Medical Instruments industry, which ranks in the top 34% of Zacks’ 250-plus industries.